The ongoing COVID-19 pandemic has impacted the market, at least partially due to the clinical uses of PDE inhibitors in diseases that exacerbate the novel SARS-CoV-2 infection, such as CVDs and obstructive pulmonary diseases (Market Data Forecast, 2022). This evidence concerns the gene ALDH7A1 and COVID-19.